UNCY:NASDAQ, Unicycive Therapeutics, Inc.
UNCY stock overview
Unicycive Therapeutics, Inc. (UNCY:NASDAQ) closed at $3.35 on November 20, 2026,
down 5.10% on the day.
The stock trades 61.7% below its 52-week high of $8.74
and 0.6% above its 52-week low of $3.33.
Over the past year, it lost 39.3%.
Unicycive Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $3.35
- Day change
- -5.10%
- Volume
- 1,355,565
- Average volume
- 958,445
- Market cap
- 97M+
- 52-week range
- $3.33 – $8.74
- 50-day average
- $4.07
- 200-day average
- $5.89
Price action over the past year
In 252 trading sessions since November 20, 2025, UNCY closed higher on 120 days (48%).
Its best day was June 22, 2026 (+14.89%) and its worst was June 30, 2026 (-39.09%).
The stock moved 10% or more in a single session 8 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
UNCY news
-
Nov 16, 2026:
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
-
Nov 4, 2026:
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
-
Oct 21, 2026:
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027
-
Oct 21, 2026:
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
-
Oct 21, 2026:
Kaplan Fox Urges Investors of Unicycive Therapeutics, Inc. (UNCY) to Seek a Leadership Role Before November 2, 2026
-
Oct 19, 2026:
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors Seeking Recovery to Contact the Firm Before November 2, 2026
-
Oct 13, 2026:
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
-
Oct 1, 2026:
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Similar stocks
Find more stocks like UNCY with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.